Moderna (MRNA)
(Delayed Data from NSDQ)
$118.75 USD
-2.43 (-2.01%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $118.84 +0.09 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.75 USD
-2.43 (-2.01%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $118.84 +0.09 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Novavax's (NVAX) COVID-19 Jab Gets Approval in Switzerland
by Zacks Equity Research
Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.
Novavax's (NVAX) COVID-19 Booster Gets CHMP Recommendation
by Zacks Equity Research
The European Medicines Agency's CHMP recommends expanded conditional marketing authorization for Novavax's (NVAX) COVID-19 vaccine as a booster for adults.
Moderna (MRNA) Down 28.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PFE, BNTX and MRNA Omicron Boosters Get Positive CHMP Opinion
by Ekta Bagri
Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.
The Zacks Analyst Blog Highlights Pfizer /BioNTec and Moderna's
by Zacks Equity Research
Pfizer /BioNTec and Moderna are part of The Zacks top Analyst Blog.
FDA Authorizes Pfizer, Moderna's Omicron-Based Boosters
by Kinjel Shah
Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) develop the Omicron BA.4/BA.5-adapted bivalent vaccines at the FDA's recommendation.
Pharma Stock Roundup: FDA Authorization of Omicron Boosters, SNY's Xenpozyme & More
by Kinjel Shah
FDA authorizes Pfizer (PFE) & Moderna's (MRNA) Omicron-aimed COVID vaccines & Sanofi's (SNY) new drug, Xenpozyme.
Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Biotech Stock Roundup: BMY's Study Update, INCY's Drug Label Expansion, MRNA News
by Zacks Equity Research
Regulatory updates from Bristol Myers (BMY) and Incyte (INCY) are a few key highlights from the biotech sector during the past week.
Moderna's (MRNA) Omicron Based Jab gets Approval in Australia
by Zacks Equity Research
Moderna (MRNA) receives provisional approval in Australia for its Omicron-containing bivalent booster vaccine mRNA-1273.214 in adults, making it the first bivalent COVID-19 vaccine approved for use in Australia.
Company News for Aug 30, 2022
by Zacks Equity Research
Companies in The News Are: HTHT,CTLT,MRNA,BA,UPS
Moderna (MRNA) Sues Pfizer and BioNTech Over COVID Jab
by Zacks Equity Research
Moderna (MRNA) sues Pfizer and BioNTech, alleging that Comirnaty infringes on patents that Moderna filed from 2010 to 2016 related to its mRNA technology.
The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Morphic
by Zacks Equity Research
Pfizer, BioNTech, Moderna and Morphic are included in this Analyst Blog.
Pfizer (PFE), BioNTech Post Data on COVID Jab for Kids Under 5
by Zacks Equity Research
Pfizer (PFE) and BioNTech (BNTX) report updated data, showing that their three-dose COVID-19 vaccine is 73.2% effective in children under five years.
Moderna (MRNA) Seeks FDA Nod for Omicron-Based COVID Jab
by Zacks Equity Research
Moderna's (MRNA) bivalent COVID-19 booster vaccine, mRNA-1273.222, is designed to target the Omicron BA.4 and BA.5 subvariants. The vaccine has been developed specifically for the U.S. market.
Moderna (MRNA) to Supply Omicron-based COVID Jab in Canada
by Zacks Equity Research
Moderna's (MRNA) Omicron-specific bivalent vaccine booster is yet to be approved by Canadian health authorities. The government seeks to purchase 12 million doses of the same in 2022.
Pfizer (PFE), BioNTech Seek FDA Nod for Omicron Variant Booster
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) Omicron BA.4/BA.5-adapted bivalent vaccine contains mRNA encoding the spike protein present in the original vaccine as well as mRNA encoding the spike protein of the Omicron BA.4/BA.5 variant.
Novavax (NVAX) COVID-19 Vaccine Gets FDA Nod for Adolescents
by Zacks Equity Research
Post the label expansion by the FDA, Novavax's (NVAX) COVID-19 vaccine is the first protein-based COVID vaccine authorized for use in individuals aged 12 years and older in the United States.
Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?
by Zacks Equity Research
Vertex's (VRTX) CF sales rise 22% in the first half of 2022, primarily driven by higher sales of Trikafta. Programs in five disease areas are now entering or progressing through late-stage clinical development.
Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates
by Zacks Equity Research
Regulatory and pipeline updates from Gilead (GILD) and Moderna (MRNA) are a few key highlights from the biotech sector during the past week.
DENTSPLY SIRONA (XRAY) Falls After Nasdaq's Delinquency Notice
by Zacks Equity Research
The Nasdaq exchange issues a notice to DENTSPLY SIRONA (XRAY) for filing delinquency from the exchange and for non-compliance with the Nasdaq Listing Rules. Shares fall.
Novavax (NVAX) Seeks FDA Authorization for COVID-19 Booster Dose
by Zacks Equity Research
Novavax (NVAX) seeks label expansion from the FDA for its COVID-19 vaccine as a booster dose in adults. The vaccine is authorized as a primary two-dose regimen in adults.
Novavax's (NVAX) COVID Vaccine Aids Growth, Overdependence Ails
by Zacks Equity Research
Currently, Novavax (NVAX) has only one marketed product in its portfolio, its protein-based COVID-19 vaccine. However, it is lagging in competition behind mRNA-based vaccines.
Should Direxion NASDAQ100 Equal Weighted Index Shares (QQQE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQE
Novavax (NVAX) Q2 Earnings Miss, Cuts '22 Sales Guidance by Half
by Zacks Equity Research
Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.